Consistent with its role as the largest biomedical cluster in Japan and the innovation arm of the City of Kobe, Kobe Biomedical Innovation Cluster (KBIC) has developed a thriving biomedical ecosystem that provides the necessary support for startup’s commercialization on a “seeds to needs” concept for startups generated by collaboration among collaborative ties in the business, academic, governmental and healthcare sectors.
To date, KBIC’s successful formula has generated numerous startups, which now comprise more than 10% of all of KBIC’s member companies.
To facilitate life science startups’ overseas expansion, KBIC has developed a full-support approach for people, goods, and money so that startups can utilize all available resources.
Here are some of the promising startups at KBIC.
Developing the next generative medicine using tissue stem cells and creating a platform where many young, promising and entrepreneurial scientists can unlock the full potential of stem cells
Funding Round: Series A
Research and development of oligonucleotides therapeutics using precise ST genome editing technology.
Funding Round: Early
PROGENICYTE JAPAN CO., LTD.
Commercialization and licensing of regenerative medicine and IT technologies developed at the University of Central Florida, College of Medicine.
Funding Round: Seed Early